B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions

Area of Science:

• Neuroimmunology
• Immunology
• Central Nervous System (CNS) Diseases

Background:

• Multiple sclerosis (MS) is a CNS autoimmune disease involving inflammation and neurodegeneration.
• Historically, T cells were considered the primary drivers, with B cells solely implicated in autoantibody production.
• Recent findings suggest antibody-independent B cell functions are critical in MS pathogenesis.

Purpose of the Study:

• To review the effects of various immunomodulatory therapies on B cell functions in MS.
• To identify new research opportunities in B cell biology and MS pathogenesis.
• To consolidate current knowledge on how MS treatments influence B cell roles.

Main Methods:

• Literature review of studies on MS treatments and B cell functions.
• Analysis of data on B cell subtype distribution and functional markers.
• Examination of cytokine secretion by B cells under different therapeutic conditions.

Main Results:

• Rituximab trials highlighted antibody-independent B cell functions (antigen presentation, costimulation, cytokine production).
• Limited data exists on how various MS therapies affect these specific B cell functions.
• Some studies show effects of first-, second-, and third-line MS treatments on B cell subtypes and markers.

Conclusions:

• B cell functions in MS are more complex than previously thought, extending beyond autoantibody production.
• Further research is needed to fully elucidate the impact of immunomodulatory therapies on antibody-independent B cell functions.
• A comprehensive understanding of these effects can lead to improved MS treatment strategies and insights into disease mechanisms.